Eucrisa (crisaborole) / Pfizer - LARVOL DELTA

Boron-Based Bioisosteres in Medicinal Chemistry: Advances in Heterocycles and Therapeutic. (PubMed, ChemMedChem) - "Benzoxaboroles have reached clinical relevance, including antifungal drugs such as tavaborole and crisaborole, as well as late-stage candidates like epetraborole and acoziborole. Benzoxaborinines and olaparib isosteres exhibit activity against carbonic anhydrases and PARP enzymes, while boronic acid drugs such as bortezomib and ixazomib are established proteasome inhibitors used in cancer therapy...Despite these advances, challenges remain regarding potency, pharmacokinetics, and mechanistic understanding of boron-target interactions. Overall, boron-based bioisosteres represent a versatile platform for developing new therapeutics across diverse disease areas."

Journal • Review • Oncology • PARP1

Utilization, cost, and specialty distribution of topical ruxolitinib prescribing in Medicare Part D, 2018-2024: A cross-sectional study. (PubMed, JAAD Int) - No abstract available

Journal • Medicare • Observational data • Reimbursement • US reimbursement • Atopic Dermatitis • Dermatitis • Dermatology • Vitiligo

Efficacy and Safety of Moisturizing Cream containing EOP(1), NP(3), & AP(6-II) Combined with Crisaborole as Adjunctive Therapy in Adult Patients with Mild Atopic Dermatitis: A Multicenter, Randomized, Parallel-Controlled Trial (EADV 2026) - No abstract available

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Rapid Repigmentation in Vitiligo with Crisaborole 2% Ointment (EADV 2026) - No abstract available

Dermatology • Immunology • Vitiligo

Efficacy and Safety of Crisaborole 2% Ointment in mild to moderate Atopic Dermatitis (EADV 2026) - No abstract available

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Real-World Clinical Outcomes of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis: A Report of Two Cases From Mexico. (PubMed, Cureus) - "We present a case series of two women with long-standing moderate-to-severe AD refractory to multiple previous therapies, including topical corticosteroids, systemic corticosteroids, topical calcineurin inhibitors, crisaborole, and, in one case, cyclosporine. No treatment-related adverse events were observed. This case series provides additional real-world evidence supporting lebrikizumab as an effective and well-tolerated treatment for moderate-to-severe AD, with rapid improvement in disease severity, pruritus, and quality of life."

Clinical data • Journal • Real-world evidence • Asthma • Atopic Dermatitis • Conjunctivitis • Dermatitis • Dermatology • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • Pruritus • Pulmonary Disease • Respiratory Diseases • IL13

Design and Synthesis of Anemoside B4 Derivatives as Pyruvate Carboxylase-Targeting Therapeutic Agents for Atopic Dermatitis. (PubMed, J Med Chem) - "In a DNCB-induced AD mouse model, topical B4-39 (6.6 mg/kg) was more effective than dexamethasone and free from its side effects, while matching the efficacy of crisaborole at a much lower dose and providing better skin barrier repair. Mechanistically, B4-39 targets pyruvate carboxylase (PC)─a novel therapeutic target in AD─modulating the TCA cycle to suppress dendritic cell activation and concurrently inhibiting NF-κB and NLRP3 inflammasome signaling. Given its enhanced efficacy, steroid-sparing safety, novel PC-targeted action, and favorable topical delivery, B4-39 is a highly promising candidate for AD treatment."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • NLRP3

The evolving landscape of phosphodiesterase inhibitors in atopic dermatitis management. (PubMed, Expert Opin Pharmacother) - "Approved agents such as crisaborole, roflumilast, and difamilast demonstrate moderate efficacy and favorable safety, mainly in mild-to-moderate AD. Emerging therapies, including apremilast, orismilast, and lotamilast, show variable results and remain under investigation...However, their efficacy is generally lower than that of biologics and JAK inhibitors. Their future role will likely depend on use as adjunctive or personalized therapies rather than replacement of high-efficacy systemic treatments."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • Pediatrics

A randomized assessor-blinded triple-arm pilot study to compare the efficacy of mometasone furoate 0.1% ointment versus crisaborole 2% ointment versus tofacitinib 2% ointment twice daily in patients with mild to moderate atopic dermatitis. (PubMed, J Am Acad Dermatol) - No abstract available

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Boron-Containing Drug Candidates in Clinical Trials. (PubMed, Handb Exp Pharmacol) - "The agents reviewed include borofalan, delanzomib, flovagatran, dutogliptin, talabostat, numidargistat, OATD-02, AN0128, epetraborole, ganfeborole, acoziborole, taniborbactam, xeruborbactam, and sodium borocaptate, as well as the five FDA-approved boroncontaining drugs (bortezomib, ixazomib, crisaborole, tavaborole, vaborbactam). The review also highlights how clinical success depends on matching pharmacology with unmet need, feasible administration, competitive differentiation, and durable development partnerships. Ongoing advances in scaffold design, delivery, combination therapy, and indication selection are expected to broaden the therapeutic impact of boron-containing medicines."

Journal • Cardiovascular • Head and Neck Cancer • Hematological Disorders • Infectious Disease • Oncology • Pulmonary Disease • Respiratory Diseases • Solid Tumor • Thrombosis • Tuberculosis

Case Report: Treatment of trachyonychia in children with crisaborole: a retrospective case series. (PubMed, Front Pediatr) - "Its small molecular weight facilitates nail matrix penetration and targets the shared inflammatory pathogenesis of trachyonychia and atopic dermatitis. Crisaborole therefore represents a promising and reliable therapeutic option for children with trachyonychia."

Journal • Retrospective data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Infectious Disease • Pediatrics

A multicenter study of crisaborole use in pediatric patients with atopic dermatitis in real-world setting in Thailand. (PubMed, Asian Pac J Allergy Immunol) - "Crisaborole treatment was associated with improved clinical outcomes and was generally well tolerated. However, the observational design and lack of a control group preclude causal conclusions regarding efficacy. Controlled studies are needed to confirm these findings."

Clinical • Journal • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pediatrics • Pruritus

Pushing the Boundaries of Topical Therapy in Patients with Atopic Dermatitis: A Review of Baseline Disease Severity and Burden in Clinical Trials. (PubMed, Dermatol Ther (Heidelb)) - "Many patients with AD treated in clinical trials of topical therapies report high levels of disease burden, overlapping with some patients eligible for systemic therapies. These results suggest that advanced topical therapies may be effective in patients with more extensive AD."

Clinical • Journal • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

TiO2-Catalyzed Borylation of Haloarenes under Visible Light and Synthesis of Benzoxaboroles. (PubMed, J Org Chem) - "The familiar boron-bearing drug molecules are tavaborole, crisaborole, bortezomib, ganfeborole, and ixazomib. A new reaction mechanism was proposed, and the radical intermediate was trapped by 2,2,6,6-tetramethyl-1-piperidinyloxy. This method was successfully applied for one-pot borylation and reduction of aldehydes, followed by cyclization under an acidic medium for the synthesis of benzoxaboroles."

Journal

A Randomized, Double-Blind, Patient-Self-Controlled Clinical Trial Evaluating the Efficacy and Safety of 2% Crisaborole Ointment Combined with 308-nm Excimer Laser for the Treatment of Non-Segmental Vitiligo (ChiCTR) - P=N/A | N=160 | Not yet recruiting | Sponsor: The Fifth People's of Hainan Province; The Fifth People's of Hainan Province

New trial • Dermatology • Immunology • Vitiligo

Efficacy and safety of crisaborole ointment combined with 308-nm excimer laser in the treatment of non-segmental vitiligo: a randomized, intra-patient left-right controlled study protocol. (PubMed, J Dermatolog Treat) - "This trial aims to provide high-quality evidence regarding the potential synergistic effect of crisaborole combined with excimer laser therapy, potentially establishing a more effective and safe treatment option for NSV. ChiCTR2600124948."

Clinical • Clinical protocol • Journal • Dermatology • Immunology • Vitiligo

Topical Therapy for Atopic Dermatitis: What is New and the New Paradigm. (PubMed, Immunol Allergy Clin North Am) - "This review summarizes their efficacy and safety data. We also review topical optimization strategies, including the recently published topical volume calculator, to maximize long-term disease control, especially when using multiple agents at the same time."

Journal • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation

Molecular modeling of 7-propanamide benzoxaboroles as CPSF3 inhibitors through docking-based 3D-QSAR and molecular dynamics simulations. (PubMed, RSC Adv) - "Benzoxaboroles are boron-based heterocycles with broad therapeutic potential, including two FDA-approved drugs, tavaborole and crisaborole. Among them, compounds 50 and 51 show enhanced pIC50 values compared to compound 32. In conclusion, this study explores SARs of benzoxaborole compounds through docking-based 3D-QSAR and MD simulations, offering valuable theoretical guidance for the rational design of new benzoxaborole derivatives as anti-cancer agents via inhibiting CPSF3."

Journal • Oncology

Synergistic antifungal effects and potential mechanisms of crisaborole combined with azoles against drug-resistant Candida albicans. (PubMed, Expert Rev Anti Infect Ther) - "In vivo efficacy of CRB plus ketoconazole (KCZ) was evaluated in a Galleria mellonella infection model, with mechanisms explored via phenotypic assays and qPCR. CRB+KCZ significantly improved larval survival, reduced fungal burden, inhibited fungal efflux pump activity, and impaired hyphal growth and host cell adhesion of C. albicans. CRB specifically enhances azoles' antifungal activity, offering a clinically translatable therapeutic strategy for drug-resistant C. albicans infections."

Journal • Candidiasis • Infectious Disease

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis (clinicaltrials.gov) - P4 | N=10 | Not yet recruiting | Sponsor: University of California, San Francisco | Initiation date: Jan 2026 ➔ Aug 2026

Trial initiation date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Psoriasis

Crisaborole 2% for Pediatric Periorificial Dermatitis: A Randomized, Double-Blind, Vehicle-Controlled Pilot Study. (PubMed, Ann Dermatol) - "While there was a modest numerical trend favoring crisaborole, its efficacy was not statistically superior to placebo in this small pilot study. Larger studies are needed to further validate the efficacy of crisaborole for the treatment for POD."

Clinical • Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pediatrics

Topical therapies for atopic dermatitis. (PubMed, J Am Acad Dermatol) - "US Food and Drug Administration-approved options include topical corticosteroids, calcineurin inhibitors, phosphodiesterase-4 inhibitors, a Janus kinase inhibitor, and an aryl hydrocarbon receptor agonist, each with different indications, efficacy, and safety considerations. Although most topical medications are studied as single agents compared with vehicle bases, in clinical practice, there is a broad set of approaches that might utilize multiple topical agents together or sequenced."

Journal • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Ten specific updates for the Mexican atopic dermatitis guidelines, GUIDAMEX 1.1. (PubMed, Bol Med Hosp Infant Mex) - "Tratamiento sistémico: dupilumab (R, ≥ 6 meses), baricitinib (S, ≥ 2 años), lebrikizumab y nemolizumab (S, ≥ 12 años); y aprobado por la FDA o la EMA, el tralokinumab (S)...Topical management: crisaborole (R, approved in Mexico for ≥ 3 months); and tapinarof, ruxolitinib, and roflumilast (S) with approvals from international agencies (FDA or EMA)...Thus, advances in atopic dermatitis allow for ambitious clinical goals. The ongoing update of GUIDAMEX offers prescribers in Mexico the latest indications and dosages for AD treatments."

Clinical guideline • Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Natural PDE4 inhibitors from plants: A comprehensive review of discovery, structure-activity relationships, and clinical translation potential. (PubMed, Eur J Med Chem) - "Although four PDE4 inhibitors have received FDA approval (roflumilast, apremilast, crisaborole, and ensifentrine), all suffer dose-limiting gastrointestinal side effects due to insufficient PDE4B/PDE4D selectivity. Despite promising potencies, critical gaps persist in subtype selectivity profiling, pharmacokinetic characterization, and metabolic stability. We propose that integrating AI-guided optimization, structure-informed isoform-selective design, nanodelivery systems, and biotechnology-enhanced production can accelerate clinical translation of these scaffolds."

Journal • Review • Asthma • Chronic Obstructive Pulmonary Disease • Dermatology • Immunology • Inflammation • Psoriasis • Pulmonary Disease • Respiratory Diseases

Topical nonsteroidal immunomodulators: A post-marketing analysis of the FDA adverse event reporting system (SID 2026) - "Agents analyzed included tacrolimus, pimecrolimus, crisaborole, ruxolitinib, roflumilast, and tapinarof...Newer generation NTIs, such as roflumilast, ruxolitinib, and tapinarof, had fewer application site-related AEs. Integrating safety data into clinical management enables balance between efficacy and patient comfort, while standardized AE reporting in future research is needed for strengthening real-world data."

Adverse events • Immunomodulating • P4 data • Acne Vulgaris • Inflammation